BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
MCB
Metropolitan Bank Holding Corp.
MCB has the edge over BAC overall, supported by stronger fundamentals and stronger valuation.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MCB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MCB's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MCB.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over MCB in the historical PE scenario, which offers more potential upside but is not a forecast.
MCB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $72.70 | -25% |
| Forward | 9x | $97.11 | — |
| Current | 9.9x | $97.11 | — |
| Fair | 11x | $105 | +8.4% |
| Expensive | 13x | $132 | +35% |
Historical ranges are pointers, not guarantees.
MCB's PE is in its fair range at 9.9x. If earnings grow as analysts expect, today's price would be 9.0x next year's earnings.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
MCB Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for MCB, with profitability improving.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over MCB on earnings, with more consistent year-over-year improvement.
MCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $10.76 | +10% |
| Q3 2026 | $9.78 | +69% |
| Q2 2026 | $7.87 | +27% |
| Q1 2026 | $8.09 | +37% |
| Q4 2025 | $6.62 | +12% |
| Q3 2025 | $5.77 | +7.6% |
| Q2 2025 | $6.18 | -1.1% |
| Q1 2025 | $5.92 | -3.3% |
| Q4 2024 | $5.93 | -14% |
MCB earned $9.78 per share over the past year, up 69% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC's revenue has grown year over year for 10 quarters in a row: $30B last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
MCB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $100.6M | +26% |
| Q2 2026 | $93M | +22% |
| Q1 2026 | $88.5M | +25% |
| Q4 2025 | $88.4M | +25% |
| Q3 2025 | $79.8M | +12% |
| Q2 2025 | $76.3M | +13% |
| Q1 2025 | $70.6M | +5.8% |
| Q4 2024 | $71M | +12% |
MCB has the edge over BAC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 46% | +33 points |
| Q2 2026 | 30% | -5.1 points |
| Q1 2026 | 50% | +17 points |
| Q4 2025 | 47% | +2.4 points |
| Q3 2025 | 13% | -12 points |
| Q2 2025 | 35% | -0.2 points |
| Q1 2025 | 33% | -3.3 points |
| Q4 2024 | 44% | +13 points |
MCB has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
MCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $61.5M | +93% |
| Q2 2026 | -$10.8M | -159% |
| Q1 2026 | $55M | +609% |
| Q4 2025 | $30.7M | -63% |
| Q3 2025 | $31.8M | +562% |
| Q2 2025 | $18.4M | -48% |
| Q1 2025 | $7.8M | -69% |
| Q4 2024 | $83.4M | +$114.2M |
MCB's free cash flow was $136M over the past year, down 3.4% from the year before. Free cash flow isn't a meaningful measure for financial services companies like MCB.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MCB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +55K shares |
| 1 year | +19% | +2M shares |
| 3 years | +13% | +1.4M shares |
| 5 years | +41% | +3.7M shares |
| Available history | +51% | +4.2M shares |
MCB has 13M diluted shares, up 19% from a year ago, despite $40M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.8M |
| Q2 2026 | — |
| Q1 2026 | $9.9M |
| Q4 2025 | $20.2M |
| Q3 2025 | $2.7M |
| Q2 2025 | $37.6M |
| Q1 2025 | $12.9M |
MCB spent $40M buying back its own shares over the past year.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MCB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.4x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | 0.4x | Very low |
MCB has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 78.7 | Neutral |
MCB's weekly RSI is 60 (neutral) and its Stochastic is 79 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
MCB PE vs Financial Services Sector
| Metric | MCB | Sector median | Relative |
|---|---|---|---|
| PE | 9.9x | 13x | 24% below |
| PE % | 44 | 63 | 19 pts below |
MCB has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
MCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $92.2 | 5.3% above |
| 20 week MA | $93.0 | 4.5% above |
| 50 week MA | $89.2 | 8.9% above |
| 100 week MA | $77.8 | 25% above |
| 200 week MA | $60.9 | 60% above |
MCB has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
MCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.9 | $35.8 | -25% |
| 2021 | $35.8 | $100.4 | +180% |
| 2022 | $100.4 | $57.9 | -42% |
| 2023 | $57.9 | $55.4 | -4.3% |
| 2024 | $55.4 | $58.2 | +5% |
| 2025 | $58.2 | $78.3 | +35% |
| 2026 YTD | $78.3 | $97.1 | +24% |
MCB has the edge over BAC on returns for 2026, with the stronger performance.